The lab firm said it now expects full-year net revenue in the range of $11.95 billion to $12.05 billion, up from its previous guidance of $11.78 billion to $11.90 billion.

The IVDR encompasses the firm's ER, PR, and Ki67 testing and completes certification of its overall digital pathology breast suite.

Precision Diabetes said on Thursday that it has acquired the exclusive US commercial rights to Nagase Diagnostics' Lucica Glycated Albumin-L assay for diabetes management. Financial and other terms of ...

The second generation test can detect the Bundibugyo strain of the virus that currently poses a threat in the Democratic Republic of the Congo and nearby countries.

The tests will help identify the inflammatory pathways involved in patients with COPD and asthma to help better guide therapy selection.

According to DOJ, the company provided consulting services at below market value to certain health care providers that referred patients to NeoGenomics for lab testing.

The firm is developing blood-based early cancer detection tests for a variety of indications, including colorectal cancer and lung cancer.

The tests are intended for infectious and chronic disease detection and diagnosis as well as to aid in routine health monitoring.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

Abbott said on Thursday that its second quarter Diagnostics sales grew 42 percent to $3.09 billion compared to $2.17 billion in the year-ago quarter, helped along by its acquisition of Exact Sciences ...

NEW YORK – Burning Rock Biotech said on Monday that it has entered into a global technology licensing agreement and strategic partnership with Myriad Genetics to expand homologous recombination ...